PROLONG-9FP clinical development program-phase i results of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP)

Thrombosis Research

Volumn 131, Issue SUPPL.2, 2013, Pages S7-

  Santagostino, Elena ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Albumin fusion protein; Factor IX; Hemophilia B; PROLONG 9FP; Recombinant albumin

Indexed keywords

ALBUMIN; BLOOD CLOTTING FACTOR; RECOMBINANT BLOOD CLOTTING FACTOR 9; RECOMBINANT FUSION PROTEIN LINKING COAGULATION FACTOR IX WITH ALBUMIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; AREA UNDER THE CURVE; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVITY; FEMALE; HEMOPHILIA B; HUMAN; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SINGLE DRUG DOSE;

EID: 84875522099     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/S0049-3848(13)70151-8     Document Type: Conference Paper

References (19)

1. GC White 2nd, A Beebe, B Nielsen Recombinant factor IX Thromb Haemost 78 1997 261 265 (Pubitemid 27289251)
2. BM Ewenstein, JH Joist, AD Shapiro et al. Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B Transfusion 42 2002 190 197
3. S Björkman, AD Shapiro, E Berntorp Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis Haemophilia 7 2001 133 139 (Pubitemid 32243794)
4. HJ Metzner, T Weimer, U Kronthaler et al. Genetic fusion to albumin improves the pharmacokinetic properties of factor IX Thromb Haemost 102 2009 634 644
5. HJ Metzner, T Weimer, S Schulte Half-life extension by fusion to recombinant albumin R Kontermann Therapeutic proteins. Strategies to modulate their plasma half-life 2012 Wiley-VCH Verlag & Co. Weinheim 223 247
6. E Santagostino, C Negrier, R Klamroth et al. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients Blood 120 2012 2405 2411
7. U Martinowitz, A Lubetsky Phase I/II, open-label, multicenter, safety, efficacy and PK study of a recombinant coagulation factor IX albumin fusion protein (rIX-FP) in subjects with hemophilia B Thromb Res 131 Suppl 2 2013 S11 S14
8. RE Kontermann Strategies to extend plasma half-lives of recombinant antibodies BioDrugs 23 2009 93 109
9. JT Andersen, I Sandlie The versatile MHC class I-related FcRn protects IgG and albumin from degradation: implications for development of new diagnostics and therapeutics Drug Metab Pharmacokinet 24 2009 318 332
10. S Schulte Use of albumin fusion technology to prolong the half-life of recombinant factor VIIa Thromb Res 122 Suppl 4 2008 S14 S19
11. AT Chemmanur, GY Wu Drug evaluation: Albuferon-α-an antiviral interferon-alpha/albumin fusion protein Curr Opin Investig Drugs 7 2006 750 758 (Pubitemid 44268848)
12. CL Anderson, C Chaudhury, J Kim et al. Perspective-FcRn transports albumin: relevance to immunology and medicine Trends Immunol 27 2006 343 348 (Pubitemid 43963476)
13. S Zeuzem, M Sulkowski, E Lawitz et al. Efficacy and safety of albinterferon alfa-2b in combination with ribavirin in treatment-naive, chronic hepatitis C genotype 1 (CHC G1) patients J Hepatol 50 Suppl 1 2009 s378 [Abstract 1041].
14. DR Nelson, V Rustgi, V Balan et al. Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis C Clin Gastroenterol Hepatol 7 2009 212 218
15. Z Yao, W Dai, J Perry et al. Effect of albumin fusion on the biodistribution of interleukin-2 Cancer Immunol Immunother 53 2004 404 410 (Pubitemid 38657253)
16. RJ Melder, BL Osborn, T Riccobene et al. Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice Cancer Immunol Immunother 54 2005 535 547
17. C Horn, B Watzka, HJ Metzner et al. Functional characterization of recombinant factor IX albumin fusion protein Hämostaseologie 32 2012 A45 [Abstract P2-45].
18. MW Nolte, TC Nichols, J Mueller-Cohrs et al. Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs J Thromb Haemost 10 2012 1591 1599
19. E Santagostino, C Negrier, R Klamroth et al. Results of a phase I international clinical trial of recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in patients with hemophilia B (PROLONG-9FP) Hämostaseologie 32 2012 A12 [Abstract ED09-7].